These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 23658373

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma.
    Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB.
    Oncologist; 2014 Apr; 19(4):354-5. PubMed ID: 24674872
    [Abstract] [Full Text] [Related]

  • 23. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 24. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M.
    Urol Oncol; 2012 Dec; 30(4):356-61. PubMed ID: 20207176
    [Abstract] [Full Text] [Related]

  • 27. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA.
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [Abstract] [Full Text] [Related]

  • 28. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ, Paul E.
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [Abstract] [Full Text] [Related]

  • 29. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T, Mis L, Hammond JM.
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [Abstract] [Full Text] [Related]

  • 30. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 31. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
    Stenner-Liewen F, Grünwald V, Greil R, Porta C.
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
    [Abstract] [Full Text] [Related]

  • 32. Temsirolimus: a safety and efficacy review.
    Bukowski RM.
    Expert Opin Drug Saf; 2012 Sep; 11(5):861-79. PubMed ID: 22861825
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB, Bivona C, Medina PJ.
    Am J Health Syst Pharm; 2010 Dec 15; 67(24):2095-106. PubMed ID: 21116000
    [Abstract] [Full Text] [Related]

  • 35. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
    Ramirez-Fort MK, Case EC, Rosen AC, Cerci FB, Wu S, Lacouture ME.
    Am J Clin Oncol; 2014 Jun 15; 37(3):266-71. PubMed ID: 23241507
    [Abstract] [Full Text] [Related]

  • 36. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct 15; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S.
    Expert Opin Investig Drugs; 2017 Nov 15; 26(11):1229-1237. PubMed ID: 28952411
    [Abstract] [Full Text] [Related]

  • 39. Adverse events associated with mTOR inhibitors.
    Pallet N, Legendre C.
    Expert Opin Drug Saf; 2013 Mar 15; 12(2):177-86. PubMed ID: 23252795
    [Abstract] [Full Text] [Related]

  • 40. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G.
    Eur J Cancer; 2017 Sep 15; 83():237-246. PubMed ID: 28756136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.